藥明康德(02359.HK)擬認購兩傢俬募基金份額 基金主投醫藥領域
格隆匯7月2日丨藥明康德(02359.HK)公佈,2020年7月1日,公司全資子企業WuXi Fund I與Nextech VIGP S.à r.l.簽署 Subscription Agreement,約定由WuXi Fund I認繳Nextech 的300萬美元份額,約佔已募集Nextech份額的0.9%。
2020年7月2日,公司全資子企業WuXi Fund I與Biospring、Biospring Partners Fund GP, LLC簽署Subscription Agreement,約定由WuXi Fund I認繳 Biospring的500萬美元份額,約佔已募集Biospring份額的27.5%。
Nextech預計募集總額為3.5億美元,WuXi Fund I本次認繳300萬美元后,Nextech已募集336,785,000美元。Nextech為一家依據盧森堡法律成立的特殊有限合夥企業,主要專注於對腫瘤治療及與之相關領域的公司進行股權投資、與股權相關的投資、債券投資以及其他形式的投資。
Biospring預計募集總額不超過2.5 億美元,WuXi Fund I本次認繳 500 萬美元后,Biospring已募集18,150,000美元。Biospring為一家依據美國特拉華州法律成立的有限合夥企業,主要專注於對在北美和英國開展業務的技術賦能型生命科學公司進行股權投資及與股權相關的投資,該等公司主要面向製藥公司、生物技術公司和學術界,側重開展服務、工具和企業軟件方面的業務。Biospring也會對該等公司的債券進行投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.